Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW


Capmatinib is a highly selective small molecule MET inhibitor. In May 2020, the U.S. FDA approved Tabrecta (Capmatinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METEX 14) mutations. Capmatinib is the first FDA-approved targeted therapy for the MET patient population.


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.